Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.
Janus kinase inhibitors: between prescription authorization and reimbursability / Spinelli, F. R.; Conti, F.; Caporali, R.; Iannone, F.; Cacciapaglia, F.; Steering Committee of the Italian Society of Rheumatology, On behalf of the. - In: REUMATISMO. - ISSN 0048-7449. - 75:4(2023), pp. 161-166. [10.4081/reumatismo.2023.1627]
Janus kinase inhibitors: between prescription authorization and reimbursability
Spinelli, F. R.;Conti, F.
;
2023
Abstract
Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria set out in the prescription forms.File allegati a questo prodotto
| File | Dimensione | Formato | |
|---|---|---|---|
|
Spinelli_Janus_2023.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
563.64 kB
Formato
Adobe PDF
|
563.64 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
